ERK1 Kinase Assay Kit

Catalog #
82282
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ ERK1 Kinase Assay Kit is designed to measure ERK1 (extracellular signal-regulated kinase 1) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant ERK1, MBP, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
Mitogen-activated protein kinase 3, Extracellular signal-regulated kinase 1 (ERK-1), Insulin-stimulated MAP2 kinase, MAP kinase isoform p44 (p44-MAPK), Microtubule-associated protein 2 kinase, p44-ERK1
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator 
Format
Catalog # Name Amount Storage
  ERK1 1.25 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
78514 MBP (5 mg/ml) 100 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
P27361
Background

ERK1 (extracellular signal-regulated kinase 1) is also known as mitogen-activated protein kinase 3 (MAPK3),  is a dual serine/threonine and tyrosine kinase. ERK (extracellular signal-regulated kinases), also known as classical MAPK (mitogen-activated protein kinases), are protein kinases involved in crucial intracellular signaling pathways, and regulate processes like mitoses, meiosis, and other functions. In the MAPK/ERK pathway Ras proteins are activated by several external molecules, including cytokines and viruses. These are followed by an activation cascade of c-Raf, MEK (mitogen-activated protein kinase kinase) and finally ERK. ERK1/2 in turn activates transcription factors. Disruption of the MAPK/ERK pathway at any point results in cancer. Inhibitors for Ras, Raf and MEK have been developed and result in rapid tumor reductions. However, resistance to treatment and relapse are quite frequent. This has led the field to focus on the development of ERK inhibitors, although these are difficult to design due to the high similarity to the CDK (cyclin-dependent kinase) pockets. Several ERK1/2 inhibitors are undergoing clinical trials aiming at treating advanced solid tumors, such as melanoma and adenocarcinoma, but further development and studies into ERK2 will open new therapeutic strategies in cancer oncology.

References

Busca R. et al., 2016 Front Cell Dev Biol 4:53.
Lavoie H., et al., 2020 Nature Reviews Molecular Cell Biology 21:607-623